Search
Streptococcus pneumoniae type 19a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10337ApprovedInvestigationalStreptococcus pneumoniae type 19a capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 19a of *Streptococcus pneumoniae
Streptococcus pneumoniae type 23f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10340ApprovedInvestigationalStreptococcus pneumoniae type 23f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 23f of *Streptococcus pneumoniae
Benziodarone
go.drugbank.com/drugs/DB13277ApprovedWithdrawnIt was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].
Succimer
go.drugbank.com/drugs/DB00566ApprovedInvestigationalA mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.
Benactyzine
go.drugbank.com/drugs/DB09023ApprovedWithdrawnBenactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.
Efavirenz
go.drugbank.com/drugs/DB00625ApprovedInvestigationalEfavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type ...
Ioversol
go.drugbank.com/drugs/DB09134ApprovedInvestigational[L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left
Synonyms: N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamideEslicarbazepine
go.drugbank.com/drugs/DB14575ApprovedEslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.
Benzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigational[L51564] Benzgalantamine was approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia in Alzheimer's patients.[L51534,L51564]